Population Pharmacokinetics of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy

被引：0
|
作者：
Arantxazu Isla
Alicia Rodríguez-Gascón
Iñaki F. Trocóniz
Lorea Bueno
María Ángeles Solinís
Javier Maynar
José Ángel Sánchez-Izquierdo
José Luis Pedraz
机构：
[1] University of the Basque Country,Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy
[2] University of Navarra,Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy
[3] Santiago Apóstol Hospital,Intensive Care Unit
[4] Doce de Octubre Hospital,Intensive Care Unit
[5] Paseo de la Universidad no 7,Laboratorio de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia
来源：
Clinical Pharmacokinetics | 2008年 / 47卷
关键词：
Minimum Inhibitory Concentration; Septic Patient; Meropenem; Continuous Renal Replacement Therapy; Patient Type;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background and objective: Meropenem is a carbapenem antibacterial frequently prescribed for the treatment of severe infections in critically ill patients, including those receiving continuous renal replacement therapy (CRRT). The objective of this study was to develop a population pharmacokinetic model of meropenem in critically ill patients undergoing CRRT.
引用
收藏
页码：173 / 180
页数：7
相关论文
共 50 条
  • [1] Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy
    Isla, Arantxazu
    Rodriguez-Gascon, Alicia
    Troconiz, Inaki F.
    Bueno, Lorea
    Angeles Solinis, Maria
    Maynar, Javier
    Angel Sanchez-Izquierdo, Jose
    Luis Pedraz, Jose
    CLINICAL PHARMACOKINETICS, 2008, 47 (03) : 173 - 180
  • [2] Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients
    J Solé Violan
    J Ferrer Agüero
    B Sádaba
    S Sancho
    R Zaragoza
    P Luque
    M Nieto
    M López
    F García
    C Hernández
    J Azanza
    Critical Care, 18 (Suppl 1):
  • [3] Population Pharmacokinetics of Tigecycline for Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
    Song, Shuping
    Liu, Jieqiong
    Su, Wei
    Yu, Haitao
    Feng, Binbin
    Wu, Yinshan
    Guo, Feng
    Yu, Zhenwei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 4459 - 4469
  • [4] Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy
    Li, Sanwang
    Xie, Feifan
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 53 (01) : 98 - 105
  • [5] Integration of Continuous Renal Replacement Therapy in a Meropenem Population Pharmacokinetics Model in Critically Ill Children
    Beranger, Agathe
    Bouazza, Naim
    Oualha, Mehdi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (04)
  • [6] Aminoglycoside Pharmacokinetics in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
    Krueger, Chelsea K.
    Bruno, Jeffrey J.
    Tverdek, Frank P.
    Hernandez, Mike
    Abudayyeh, Ala
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (06) : 629 - 636
  • [7] Daptomycin pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy
    Rudiger, Alain
    Rentsch, Katharina
    Maggiorini, Marco
    Corti, Natascia
    CRITICAL CARE MEDICINE, 2011, 39 (05) : 1243 - 1244
  • [8] Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
    He, Sha
    Cheng, Zeneng
    Xie, Feifan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 13 - 22
  • [9] Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy
    Xie, Feifan
    Li, Sanwang
    Cheng, Zeneng
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (06) : 1559 - 1566
  • [10] Daptomycin pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy reply
    Vilay, A. Mary
    DePestel, Daryl D.
    Mueller, Bruce A.
    CRITICAL CARE MEDICINE, 2011, 39 (05) : 1244 - 1245
12345